TipHub

₹1.9

■ +0 +0.00%

As of 27 Jul 2026 · delayed

BSE Listed

GSM · GSM 4
What does GSM · GSM 4 mean?
BSE · Graded Surveillance Measure (GSM 4)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).Exchange notice · 2026-06-09

Advik Laboratories Ltd. (531686)

Volume: 0Avg Vol 1W: 730Avg Vol 1M: 9,03952W Range:₹1.57₹2.47
BSE www.mpspharmaa.com AI Report
Key Ratios
Checked 3h ago
Market Cap₹4 Cr
Current Price₹1.9
Previous Close₹1.9
High / Low (52w)₹2.47 / ₹1.57
Volume0
Avg Vol (1W)730
Avg Vol (1M)9,039
Stock P/E—
Book Value₹0.04
Dividend Yield0%
ROE-1,489.05%
ROA-12.03%
Revenue (TTM)—
Revenue Growth—
Profit Margin0%
Total Debt—
Shares Outstanding2 Cr
Face Value—
EPS (TTM)₹0
P/B50.86
Debt / Equity4.83
50 DMA₹2.01
200 DMA—
Day change+0.00%
SurveillanceGSM · GSM 4
Price Chart
₹1.9▼ 20.83% · 1Y
₹4₹299K
2025-08-04
2026-07-27

20-day avg volume: 10K shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 49% YoY.
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹4 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹-1 Cr₹-1 Cr₹-1 Cr₹-4 Cr₹-1 Cr₹-1 Cr₹-1 Cr₹-1 Cr
Net Profit₹-1 Cr₹-1 Cr₹-1 Cr₹-4 Cr₹0 Cr₹-1 Cr₹-1 Cr₹-1 Cr
EPS-0.44-0.65-0.61-2.31-0.07-0.55-0.43-0.47
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹19 Cr₹18 Cr₹16 Cr₹11 Cr₹10 Cr₹10 Cr₹10 Cr₹9 Cr
Total Liabilities₹8 Cr₹8 Cr₹8 Cr₹7 Cr₹6 Cr₹7 Cr₹8 Cr₹8 Cr
Equity₹11 Cr₹10 Cr₹8 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr₹1 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹-1 Cr₹-4 Cr₹-1 Cr₹-1 Cr₹-1 Cr
Investing₹2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Financing₹-1 Cr₹4 Cr₹1 Cr₹1 Cr₹0 Cr
Free Cash Flow₹-1 Cr₹-4 Cr₹-1 Cr₹-1 Cr₹-1 Cr
Shareholding
Promoter 35.89% Institutions 0.58% Public 63.53%
Efficiency & Working Capital
ROCE-13.9%
Interest Coverage0
Dividend Payout—
Debtor Days—
Inventory Days—
Payable Days—
Cash Conversion Cycle—
Working Capital Days—
Shareholding Details

As of 2026-06-30

Promoter35.9%
FII0%
DII0.6%
Institutions0.6%
Public63.5%
Promoter Pledge16%
No. of Shareholders4,409
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters35.9%35.9%35.9%35.9%35.9%35.9%35.9%35.9%35.9%35.9%35.9%35.9%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0.6%0%0.6%0.6%0.6%0.6%0.6%0.6%0.6%0.6%0.6%0.6%
Public63.5%64.1%63.5%63.5%63.5%63.5%63.5%63.5%63.5%63.5%63.5%63.5%
Promoter Pledge16%16%16%16%16%16%16%16%16%16%16%16%
No. of Shareholders4,4544,4354,4144,3984,3864,3974,4224,4454,4334,4254,4194,409
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Omkam Pharmaceuticals Private LimitedShareholding of Promoter and Promoter Group25.7%49,02,322
Pataliputra International LimitedPublic Shareholding17.5%33,47,325
Peeyush Kumar AggarwalShareholding of Promoter and Promoter Group10.2%19,57,159
Sangeetha SPublic Shareholding6.2%11,89,720
Dhiru Builders And Promoters Private LimitedPublic Shareholding5.2%10,00,000
Sneha GargPublic Shareholding2%3,85,000
Geeta GargPublic Shareholding2%3,80,000
Sampark Securities Pvt LtdPublic Shareholding1.1%2,03,229
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Omkam Pharmaceuticals Private Limited11,00,00022.4%2026-06-30
Board of Directors
NameDesignationYear
Peeyush Kumar AggarwalChairman / Executive Director / M D / Promoter2025
Madhu SharmaIndependent Non Exe. Director2025
Ram Niwas SharmaNon-Exec & Non-Independent Dir2025
Ajay SharmaIndependent Non Exe. Director2025
Pooja ChuniCompany Sec. & Compli. Officer2025
Segments — Geography
RegionRevenueShare
In India₹1 Cr100%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10202019
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000000
2025000000
2025000000
Substantial Acquisitions (SAST)

6 disclosure(s)

Market12/07/2021 · 42,12,325
Market12/07/2021 · 42,12,325
Market12/07/2021 · 26,29,000
Market & Off Market12/07/2021 · 26,29,000
Off Market12/07/2021 · 16,05,270
Off Market12/07/2021 · 16,05,270
Company Information
Incorporated1994
ChairmanPeeyush Kumar Aggarwal
AuditorNemani Garg Agarwal & Co
Investor Email[email protected], [email protected]
🌐 www.mpspharmaa.com ↗

📍 138 Roz-Ka-Meo Industrial Area, Sohna, Mewat, Haryana, 122103

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Anka India Ltd.Emrock Corporation LimitedAris International Ltd.Mayur Leather Products Ltd.Amerise Biosciences LimitedFrontline Financial Services Ltd.Prithvi Exchange (India) Ltd.Khyati Multimedia Entertainment Ltd.Rainbow Foundations Ltd.VSD Confin Ltd.Tricom Fruit Products LimitedVidhi Specialty Food IngredientsAll “53” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search